Key result
Inactivated EV71 vaccine has ~25% first-dose coverage with low adverse event rates across manufacturers.
Why the study?
Since China approved inactivated enterovirus 71 vaccines from three manufacturers in 2016, the coverage and safety of the different vaccines needed to be evaluated.
What is the coverage and safety of inactivated EV71 vaccines among children in Guangzhou?
Observational (n=2,781,618)
What is the coverage and safety of inactivated EV71 vaccines among children in Guangzhou?
The EV71 vaccines demonstrated good safety profiles, but overall coverage rates among children in Guangzhou remain low, highlighting the need for increased vaccine promotion.
Answers are grounded in this paper and cite their sources.
Reassuring safety supports continued use; leaves open effective strategies to raise coverage in similar settings.
Background: Since 2016, China has approved the use of inactivated enterovirus 71 (EV71) vaccines produced by three manufacturers. The coverage and safety of different EV71 vaccines need to be evaluated.Research design and methods: The EV71 vaccination and AEFI data were collected from the Guangzhou Children’s Vaccination Information Report Management System and the China AEFI Monitoring Information Management System, and the EV71 vaccine coverage rate and the AEFI incidence rate were analyzed.Results: From 2016 to 2019, the number of people who should have been vaccinated in Guangzhou was 2,781,618, and the coverage rates for doses 1 and 2 were 24.71% and 19.44%, respectively. The inoculation rates of vaccines from manufacturers A and B were between 3.03 and 10.46%. The reported incidence of AEFIs was 11.97 per 100,000 (147 cases), with fever (106 cases, 8.63 per 100,000) and allergic rash (59 cases, 4.80 per 100,000) being the most common reactions. There were no differences in the AEFI responses to the EV71 vaccines from the three manufacturers.Conclusion: The EV71 vaccines from the three manufacturers have good safety, but the EV71 vaccine coverage rate is low. It is recommended that vaccine publicity be strengthened and that the vaccine coverage rate in children be increased.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted an observational in Healthy children eligible for vaccination (n=2,781,618). Inactivated enterovirus 71 (EV71) vaccine was evaluated on Vaccine coverage rate and adverse events following immunization (AEFI) incidence rate. Inactivated EV71 vaccine coverage among children in Guangzhou was low, with a reported adverse event incidence of 11.97 per 100,000 and no differences among manufacturers.
Synapse has enriched 10 related papers. Consider them for comparative context: